Anna Eramo - 10 Sep 2025 Form 4 Insider Report for LB PHARMACEUTICALS INC

Reporting relationship: Chief Medical Officer
Issuer ticker: LBRX on Nasdaq
Reported as of: 10 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Sep 2025, 18:25:09 UTC
Source filing: View source filing
Reporting owner signature: /s/ Marc Panoff, Attorney-in-Fact

Key filing fact

Anna Eramo filed Form 4 for LB PHARMACEUTICALS INC on 12 Sep 2025.

Key facts

This page summarizes Anna Eramo's Form 4 filing for LB PHARMACEUTICALS INC.
5 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 12 Sep 2025, 18:25.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002030921 Primary reporting owner

Eramo Anna

Relationship: Chief Medical Officer
Address: C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK
Signature: /s/ Marc Panoff, Attorney-in-Fact
Signature date: 12 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LBRX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -26,893
Change %: -100%
Price
Shares after: 0
Date: 10 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,893
Exercise price: $41.84
Footnotes: F1, F2

LBRX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +26,893
Change %
Price
Shares after: 26,893
Date: 10 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,893
Exercise price: $15.00
Footnotes: F1, F2

LBRX transaction Derivative

Employee Stock Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -6,275
Change %: -100%
Price
Shares after: 0
Date: 10 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,275
Exercise price: $41.84
Footnotes: F2, F3

LBRX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +6,275
Change %
Price
Shares after: 6,275
Date: 10 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,275
Exercise price: $15.00
Footnotes: F2, F3

LBRX transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +155,812
Change %
Price: $0.000000
Shares after: 155,812
Date: 10 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 155,812
Exercise price: $15.00
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

One fourth (1/4) of the shares subject to the option award vested on August 25, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Footnote F2

The transactions reported herein reflect a one-time stock option repricing, effective on September 10, 2025, which reduced the per share exercise price of each repriced option to $15, representing the initial public offering price of the Issuer's common stock (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the repriced options, including, without limitation, any provisions with respect to vesting, remain in full force and effect.

Footnote F3

One fourth (1/4) of the shares subject to the option award vested on June 28, 2025 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Footnote F4

One fourth (1/4) of the shares subject to the option award shall vest on September 10, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.